Underwriter
Alpha Teknova, Inc.
Equity Capital Markets
Follow-On Offering
Transaction Details
On October 20, 2026, Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO) announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share
Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock
All of the shares of common stock in the offering are to be sold by Teknova
Teknova currently intends to use the net proceeds from this offering for general corporate purposes, including potentially the repayment of outstanding debt obligations
- Teknova may use a portion of the net proceeds to acquire or invest in other businesses, products, and technologies that are complementary to its own, although Teknova has no current commitments or arrangements to do so
About the company
Alpha Teknova, Inc. (Nasdaq: TKNO) makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. Teknova offers fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Teknova’s fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps its customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by its team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
-
Sources: Company Filings and Press Release.
This material has been prepared solely for informational purposes as of its stated date. It is not a solicitation, recommendation or offer to buy or sell any security and does not provide information on which an investment decision to purchase or sell any securities could be based. It does not purport to be a complete description of the securities, markets or developments referred to in this material. All information and data included in this material has been sourced from company announcements and other sources cited in this material, but Stephens has not independently verified such information and does not guarantee that it is accurate or complete. No subsequent publication or distribution of this material shall mean or imply that any such information remains current at any time after the date of preparation of this material. Stephens does not undertake to advise you of any changes in any such information. Additional information is available upon request.
The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Stephens Inc.’s Equity Syndicate Desk, at Stephens Inc., 111 Center Street, Little Rock, AR 72201, ATTN: Equity Syndicate Desk, or from the Securities and Exchange Commission’s website at www.sec.gov at the following link: https://www.sec.gov/Archives/edgar/data/1850902/000119312526426674/d179208d424b5.htm. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to the notice of its acceptance given after the effective date.
“Stephens” (the company brand name) is a leading family-owned investment firm that includes Stephens Inc. (member NYSE/SIPC), Stephens Investment Management Group, LLC, Stephens Insurance, LLC, Stephens Capital Partners LLC and Stephens Europe Limited (Registered office: 12 Arthur Street, London, EC4R 9AB, Registered number 8817024), which is authorised and regulated by the Financial Conduct Authority. © 2026 Stephens.